Serum WFA+ -M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection.
about
Serum WFA(+) -M2BP levels predict liver fibrosis, development of hepatocellular carcinoma, and overall survival: A meta-analysis.Impact of Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein in Patients with Hepatitis C Virus-Related Compensated Liver Cirrhosis.Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatmentSerum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients.Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis.High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.Wisteria floribunda agglutinin positive glycobiomarkers: a unique lectin as a serum biomarker probe in various diseases.Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients.Increased serum Wisteria floribunda agglutinin positive Mac-2 binding protein (Mac-2 binding protein glycosylation isomer) in chronic heart failure: a pilot study.Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis.Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection.Diagnosis of Liver Fibrosis With Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFA-M2BP) Among Chronic Hepatitis B Patients.
P2860
Q40244120-4AA2E114-AD77-43B3-8B4B-EA9EA3CF8F14Q40582320-E449560D-2FD7-4785-B48B-E2291DFB849AQ41471144-52782AC9-5DBE-42E0-BB6B-99F7BF030B9EQ43695910-A2B36E0C-9127-4DFE-96D8-4D328A171A8DQ47215149-47C1171C-0E18-4710-95E7-F496ED05EA81Q47243952-3D0E92B3-B392-4584-87F2-52EB9F7D580AQ47266548-4108F34F-DC80-430B-9111-904EAEE41AA8Q47286873-81FB9036-74FA-4414-8801-4B0236563329Q47446628-C5B92A07-D464-4833-8127-ABDA0728EFAEQ47890590-9C9ACDF8-813B-4B1E-AB21-DDE694BCAEEDQ52699064-D657A8D8-103F-4A59-A542-B68DC902A215Q55276444-6B85C745-10A0-42E0-9C25-9A0C092FDC9FQ55376294-4420B118-27D2-476B-A829-A81C2A040B69
P2860
Serum WFA+ -M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Serum WFA+ -M2BP levels for ev ...... c hepatitis B virus infection.
@en
type
label
Serum WFA+ -M2BP levels for ev ...... c hepatitis B virus infection.
@en
prefLabel
Serum WFA+ -M2BP levels for ev ...... c hepatitis B virus infection.
@en
P2093
P2860
P356
P1433
P1476
Serum WFA+ -M2BP levels for ev ...... ic hepatitis B virus infection
@en
P2093
Dong-Hua Zhang
Fei-Jie Lu
Jie-Hong Jiang
Min-Hua Zheng
Ming-Yu Zhu
Qi-Ming Gong
P2860
P356
10.1111/LIV.13188
P577
2016-07-12T00:00:00Z